Company
Aukera Therapeutics
- AI
- Biotech
- Location:
- Basel, Switzerland
Description
Aukera Therapeutics develops the first RAPTOR inhibitors, using an AI-driven drug discovery platform and mTOR biology expertise to design and advance preclinical therapeutics for mTORC1-related pathologies.
Related
Qubit PharmaceuticalsQubit Pharmaceuticals develops quantum- and AI-driven molecular modeling platforms and drug discovery tools used to design novel drug…
HealxHealx builds AI-driven drug discovery and development tools and therapies for rare disease patients, applying AI across discovery,…
EvotecEvotec provides integrated drug discovery and preclinical development services, delivering CRO/CDMO research platforms, ADME‑Tox, biologics…
KvantifyKvantify develops software and services that route calculations across quantum and classical architectures, accelerating molecular…
WhiteLab GenomicsWhiteLab Genomics builds AI-driven computational platforms to design and optimize genomic medicines, producing in‑silico modules and…
IktosIktos builds generative AI and robotics systems for drug discovery, producing platforms for de novo molecule design, retrosynthesis…
ZoBioZoBio helps biopharma companies identify small molecules for drug targets, applying protein-science expertise, biophysical and biochemical…
InSpheroInSphero provides human-tissue 3D in vitro cell-culture models, spheroid and organoid tools, and automation-compatible plates that support…
Engimmune Therapeutics AGEngimmune Therapeutics AG engineers soluble T‑cell receptor (TCR) therapeutics using AI‑guided protein engineering to create multispecific,…